Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Treatment Period (Baseline to Week 16)	STARTED	Secukinumab 300 mg	14
Treatment Period (Baseline to Week 16)	STARTED	Placebo	14
Treatment Period (Baseline to Week 16)	COMPLETED	Secukinumab 300 mg	12
Treatment Period (Baseline to Week 16)	COMPLETED	Placebo	12
Treatment Period (Baseline to Week 16)	NOT COMPLETED	Secukinumab 300 mg	2
Treatment Period (Baseline to Week 16)	NOT COMPLETED	Placebo	2
Follow-up Period (Week 16 to Week 108)	STARTED	Secukinumab 300 mg	12
Follow-up Period (Week 16 to Week 108)	STARTED	Placebo	12
Follow-up Period (Week 16 to Week 108)	COMPLETED	Secukinumab 300 mg	8
Follow-up Period (Week 16 to Week 108)	COMPLETED	Placebo	9
Follow-up Period (Week 16 to Week 108)	NOT COMPLETED	Secukinumab 300 mg	4
Follow-up Period (Week 16 to Week 108)	NOT COMPLETED	Placebo	3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04737330/flow